TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25213687

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy (routine medications replaced with study regimen to achieve blood pressure <140/90 mm Hg)
Number of subjects: 47
Study: 23462943

Group type: EXPERIMENTAL
Intervention: Dairy/Ca (high dairy, ≈ 1400 mg/day Ca, ‐500 kcal/day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (low dairy, ≈ 700 mg/day Ca, ‐500 kcal/day)
Number of subjects: 49
Study: 22263599

Group type: EXPERIMENTAL
Intervention: 40 g white sesame seeds daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (not specified, but 240 kcal removed from diet)
Number of subjects: 38
Study: 20225466

Group type: EXPERIMENTAL
Intervention: Clearfil Tri‐S Bond
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: G‐Bond
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Adper Single Bond
Number of subjects: 4

Group type: COMPARATOR
Intervention: One-step adhesives (Clearfil Tri‐S Bond and G‐Bond)
Number of subjects: 4
Study: 17541495

Group type: EXPERIMENTAL
Intervention: Inversion of the transversalis fascia (TF) during laparoscopic inguinal hernia repair
Number of subjects: 216

Group type: COMPARATOR
Intervention: No inversion of the transversalis fascia (TF) during laparoscopic inguinal hernia repair
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Inversion of the transversalis fascia (TF)
Number of subjects: 216

Group type: COMPARATOR
Intervention: No inversion of the transversalis fascia (TF)
Number of subjects: 216
Study: 15197051

Group type: EXPERIMENTAL
Intervention: Echinacea purpurea (100 mg, freeze-dried pressed juice from the aerial portion of the plant) 3 times daily until symptoms relieved or 14 days
Number of subjects: 128

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 128
Study: 11479480

Group type: COMPARATOR
Intervention: Aspirin (ASA) monotherapy, n = 16
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined therapy with ticlopidine (TIC) and ASA, n = 16
Number of subjects: 48

Group type: COMPARATOR
Intervention: No antiplatelet drug (patient control), n = 16
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All groups (including ASA and TIC therapy)
Number of subjects: 48
Study: 9828641

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Control group (conventional laser coagulation)
Number of subjects: 609
Study: 7830324

Group type: EXPERIMENTAL
Intervention: Special care (therapeutic drug regimens including clonidine, nifedipine, atenolol+chlorthalidone)
Number of subjects: 655

Group type: COMPARATOR
Intervention: Free therapy (by personal physicians without special intervention)
Number of subjects: 655

Group type: COMPARATOR
Intervention: Normotensive subjects (control group)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Fixed combination of atenolol and chlorthalidone
Number of subjects: 655
Study: 2974778

Group type: EXPERIMENTAL
Intervention: Group education by diabetes specialist nurses and a dietitian (5 sessions of 90 minutes each over 6 months)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Group education by diabetes specialist nurses and a dietitian
Number of subjects: 75
Study: 30296920

Group type: EXPERIMENTAL
Intervention: Superficial dry needling (SDN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Deep dry needling (DDN)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pressure pain threshold (PPT) measurements
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Visual analog scale scores
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Maximal jaw opening
Number of subjects: 40
Study: 29579320

Group type: EXPERIMENTAL
Intervention: Platysma muscle suture
Number of subjects: 82

Group type: COMPARATOR
Intervention: No platysma muscle suture
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study: 28439597

Group type: EXPERIMENTAL
Intervention: Ambu AuraOnce
Number of subjects: 112

Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 112
Study: 25617119

Group type: EXPERIMENTAL
Intervention: Novasial (oral saliva equivalent) administered four times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aequasyal (oxygenated glycerol triester oral spray)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biotene (moisturizing spray)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novasial
Number of subjects: 0
Study: 24066182

Group type: EXPERIMENTAL
Intervention: Open Reduction and Internal Fixation (ORIF)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 130
Study: 21336679

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy-based weight management program (n=44)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (n=24)
Number of subjects: 68
Study: 18297435

Group type: EXPERIMENTAL
Intervention: Pan-colonic NBI system
Number of subjects: 243

Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 243
Study: 16553016

Group type: EXPERIMENTAL
Intervention: Clonidine 0.3 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Propranolol 120 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 14585211

Group type: EXPERIMENTAL
Intervention: bivalent HIV gp120 SF2/CM235 vaccine
Number of subjects: 12
Study: 10938185

Group type: EXPERIMENTAL
Intervention: Hydroquinidine (450 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8751695

Group type: EXPERIMENTAL
Intervention: Injection at 4 ml/sec with a 25-sec scan delay
Number of subjects: 217

Group type: COMPARATOR
Intervention: Injection at 4 ml/sec with a 20-sec scan delay
Number of subjects: 217

Group type: COMPARATOR
Intervention: Injection at 2 ml/sec with a 30-sec scan delay
Number of subjects: 217

Group type: COMPARATOR
Intervention: Injection at 2 ml/sec with a 35-sec scan delay
Number of subjects: 217

Group type: COMPARATOR
Intervention: Injection at 2 ml/sec
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Injection at 4 ml/sec
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Arterial-phase helical CT
Number of subjects: 217

Group type: COMPARATOR
Intervention: Portal-venous phase helical CT
Number of subjects: 217
Study: 1574965

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r-HuEPO) at a dose of 100 U/kg given intravenously twice weekly for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2410117

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 32 mg daily for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 40
Study: 31269914

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) for 8 weeks, 3 times weekly, with an average of 78 ± 5.1 minutes of exercise completed out of 90 minutes.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-exercise control group (CON)
Number of subjects: 30
Study: 29703226

Group type: EXPERIMENTAL
Intervention: Individualised Modular Treatment Programme (IMTP) - 10 sessions of individual cognitive behavioural therapy with adolescents and/or parents, focusing on three out of ten available modules.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Telephone-assisted self-help programme for parents (TASH) - combines bibliotherapeutic components with 10 counselling sessions for parents via telephone.
Number of subjects: 160
Study: 27164293

Group type: EXPERIMENTAL
Intervention: High-dose exercise (16 kcal/kg of weight/week)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Low-dose exercise (4 kcal/kg of weight/week)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 122
Study: 24659192

Group type: EXPERIMENTAL
Intervention: Probability training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teaming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tracking (top 2% from Year 1 in elite teams)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical algorithms (reported elsewhere)
Number of subjects: 0
Study: 22153001

Group type: EXPERIMENTAL
Intervention: Fractional inactivated poliovirus vaccine (IPV) administered intradermally (ID)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Full dose inactivated poliovirus vaccine (IPV) administered intramuscularly (IM)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fractional IPV dose administered by ID route
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Booster dose of IPV
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adverse events monitoring
Number of subjects: 100
Study: 20499357

Group type: EXPERIMENTAL
Intervention: Once-yearly i.v. infusion of ZOL 5 mg
Number of subjects: 302

Group type: COMPARATOR
Intervention: Once-weekly oral ALN 70 mg
Number of subjects: 302
Study: 17539899

Group type: EXPERIMENTAL
Intervention: Genetic test scenario (high-risk result)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Oxidative test scenario (high-risk result)
Number of subjects: 261
Study: 15186610

Group type: EXPERIMENTAL
Intervention: TRIAC 0.03%
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: TRIAC 0.1%
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11441544

Group type: EXPERIMENTAL
Intervention: Vicryl Rapide suture (n = 61)
Number of subjects: 101

Group type: COMPARATOR
Intervention: 3‐0 Supramid suture (n = 40)
Number of subjects: 101
Study: 9850068

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg twice a day) plus rhEPO (12,000-30,000 units per week)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Indomethacin (50 mg twice a day)
Number of subjects: 108
Study: 7851281

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.15‐0.9 mg/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Clonidine (0.3‐0.9 mg/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lefetamine (60‐240 mg/day)
Number of subjects: 39
Study: 2670659

Group type: EXPERIMENTAL
Intervention: Sucralfate suspension, 4 g/day (10 ml four times a day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sucralfate suspension
Number of subjects: 19
Study: 73797

Group type: EXPERIMENTAL
Intervention: Cimetidine 1.6 g daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cimetidine 0.8 g daily
Number of subjects: 47
Study: 31008633

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 87
Study: 27859629

Group type: EXPERIMENTAL
Intervention: Intravenous Escherichia coli lipopolysaccharide (LPS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Endobronchial Escherichia coli lipopolysaccharide (LPS)
Number of subjects: 15
Study: 26118427

Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 1,000 mg once-daily (QD)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 600 mg QD and ribavirin (RBV)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 800 mg QD and ribavirin (RBV)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 600 mg QD and pegylated interferon (Peg-IFN)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Pegylated interferon (Peg-IFN) and ribavirin (RBV)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) and ribavirin (RBV) after rapid virological response (RVR)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) alone after rapid virological response (RVR)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Pegylated interferon (Peg-IFN) and ribavirin (RBV) after rapid virological response (RVR)
Number of subjects: 340
Study: 23547804

Group type: EXPERIMENTAL
Intervention: High Osteoprotegerin (OPG) levels
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Unadjusted survival analysis of OPG
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Adjusted analyses of OPG
Number of subjects: 206
Study: 21596740

Group type: EXPERIMENTAL
Intervention: Surgery with disc prosthesis
Number of subjects: 173

Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 173
Study: 19644361

Group type: EXPERIMENTAL
Intervention: NT 201 (median, 320 U)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 16160652

Group type: EXPERIMENTAL
Intervention: Brain perfusion SPECT with 99mTc-ECD
Number of subjects: 16
Study: 12298188

Group type: EXPERIMENTAL
Intervention: Enalapril and captopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normotensive persons)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated hypertensive subjects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (including enalapril and captopril)
Number of subjects: 0
Study: 10091877

Group type: EXPERIMENTAL
Intervention: Rifater (combined formulation of isoniazid, rifampicin, and pyrazinamide)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Separate drugs (isoniazid, rifampicin, and pyrazinamide)
Number of subjects: 310
Study: 7500544

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1.8 g/day, n = 12
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no EPA treatment), n = 10
Number of subjects: 22
Study: 2264174

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) vaginal tablets
Number of subjects: 88

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 88
Study: 7386409

Group type: EXPERIMENTAL
Intervention: 100 g of cream fat
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 100 g of saffola oil
Number of subjects: 11

Group type: COMPARATOR
Intervention: Isocaloric nonfat cornstarch control meal
Number of subjects: 11
Study: 30482392

Group type: EXPERIMENTAL
Intervention: Apremilast, 30 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28057030

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.5 mmol/kg loading dose for 1 hour, followed by 0.15 mmol/kg/h infusion for 23 hours)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sodium chloride (control)
Number of subjects: 70
Study: 25646324

Group type: EXPERIMENTAL
Intervention: High whey protein-, leucine-, and vitamin D-enriched supplement (150 kcal, 21 g protein; 10×/wk)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isocaloric control
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High whey protein-, leucine-, and vitamin D-enriched supplement
Number of subjects: 80
Study: 22540676

Group type: EXPERIMENTAL
Intervention: Immediate functionally loaded implants (test implants)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Non-loaded implants (control implants)
Number of subjects: 13
Study: 21359615

Group type: EXPERIMENTAL
Intervention: 0.1% triamcinolone acetonide paste (0.5 mg)
Number of subjects: 143

Group type: COMPARATOR
Intervention: 0.1% chlorhexidine gluconate jelly
Number of subjects: 143
Study: 19302265

Group type: EXPERIMENTAL
Intervention: Octreotide at doses >=0.5 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Octreotide at doses <0.5 mg
Number of subjects: 18
Study: 16647307

Group type: EXPERIMENTAL
Intervention: Combination B vaccine
Number of subjects: 0
Study: 15519082

Group type: EXPERIMENTAL
Intervention: Anterior capsule polishing
Number of subjects: 52

Group type: COMPARATOR
Intervention: Anterior capsule polishing (SI-40 IOL)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Anterior capsule polishing (Silens6 IOL)
Number of subjects: 52
Study: 11485707

Group type: EXPERIMENTAL
Intervention: Telephone management
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual office-based care
Number of subjects: 72
Study: 9684213

Group type: EXPERIMENTAL
Intervention: Psychoeducational group approach to self-management (16 group sessions)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (25 individuals)
Number of subjects: 88
Study: 8111941

Group type: EXPERIMENTAL
Intervention: Atracurium 0.07 mg.kg‐1
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pancuronium 0.015 mg.kg‐1
Number of subjects: 52
Study: 2460831

Group type: EXPERIMENTAL
Intervention: Catheter reuse during electrophysiologic studies
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single use of pacing catheters
Number of subjects: 12
Study: 29178126

Group type: EXPERIMENTAL
Intervention: McGrath VL
Number of subjects: 84

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 84
Study: 26843140

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation of 1200 IU d−1 for 11 months
Number of subjects: 132
Study: 26424831

Group type: EXPERIMENTAL
Intervention: Maternal antiretrovirals
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Infant nevirapine
Number of subjects: 2369

Group type: COMPARATOR
Intervention: Neither intervention
Number of subjects: 2369
Study: 24622227

Group type: EXPERIMENTAL
Intervention: Exercise intervention group
Number of subjects: 117

Group type: COMPARATOR
Intervention: Health-education group
Number of subjects: 117
Study: 21409424

Group type: EXPERIMENTAL
Intervention: Midazolam combined with fentanyl (50-100 mg)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Midazolam combined with propofol (0.5-2.5 mg/kg)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Midazolam alone (1.0-2.0 mg)
Number of subjects: 480
Study: 18182121

Group type: EXPERIMENTAL
Intervention: Nifedipine infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 20
Study: 16357087

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (CPAP) for 14 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo CPAP (administered at ineffective pressure)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oxygen supplementation
Number of subjects: 50
Study: 12571128

Group type: EXPERIMENTAL
Intervention: Whole body skin cooling (water‐perfused suits) at 0600 (AM) and 1600 (PM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole body skin cooling (water‐perfused suits) at 0600 (AM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole body skin cooling (water‐perfused suits) at 1600 (PM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole body skin cooling (water‐perfused suits)
Number of subjects: 0
Study: 10487284

Group type: EXPERIMENTAL
Intervention: Sandimmune cyclosporin A 2.5 mg/kg b.i.d.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neoral cyclosporin A 2.5 mg/kg b.i.d.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Limited sampling model including concentration data at 2 and 12 h
Number of subjects: 10
Study: 8522675

Group type: EXPERIMENTAL
Intervention: Flow-triggered (FT) system
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pressure-triggered (PT) system
Number of subjects: 10
Study: 1682787

Group type: EXPERIMENTAL
Intervention: MK-912 (2 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6786131

Group type: COMPARATOR
Intervention: Tidal volume of 6 ml/kg bodyweight
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tidal volume of 15 ml/kg bodyweight
Number of subjects: 20
Study: 31246068

Group type: COMPARATOR
Intervention: Contingency Management (CM)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: CM plus Working Memory Training (WMT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Working Memory Training (WMT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Higher magnitude CM (Phase 2)
Number of subjects: 59
Study: 27758729

Group type: EXPERIMENTAL
Intervention: Social problem-solving training (SPST) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 25868406

Group type: EXPERIMENTAL
Intervention: Laparoscopic mesh‐augmented hiatoplasty with simple cardiophrenicopexy (LMAH‐C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laparoscopic mesh‐augmented hiatoplasty with fundoplication (LMAH‐F)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study: 24289488

Group type: EXPERIMENTAL
Intervention: FACT-G
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: CLAD model for EQ-5D
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: GLM model for SF-6D
Number of subjects: 367
Study: 21473827

Group type: EXPERIMENTAL
Intervention: PEEP levels of 10 cm H(2)O and 14 cm H(2)O in poor cardiac function group (n=19)
Number of subjects: 36

Group type: COMPARATOR
Intervention: PEEP levels of 0 cm H(2)O in poor cardiac function group (n=19)
Number of subjects: 36

Group type: COMPARATOR
Intervention: PEEP levels of 0 cm H(2)O in normal cardiac function group (n=17)
Number of subjects: 36
Study: 19854329

Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 16000

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 16000
Study: 17822972

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (1.0%)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Fortified tobramycin/cephazolin
Number of subjects: 229

Group type: COMPARATOR
Intervention: Ofloxacin (0.3%)
Number of subjects: 229
Study: 14756739

Group type: EXPERIMENTAL
Intervention: Total Abdominal Hysterectomy (TAH)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Subtotal Abdominal Hysterectomy (SAH)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Total Abdominal Hysterectomy (TAH) and Subtotal Abdominal Hysterectomy (SAH)
Number of subjects: 319
Study: 11477318

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GJ)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Losartan without grapefruit juice
Number of subjects: 9
Study: 10690857

Group type: EXPERIMENTAL
Intervention: GH + LH-releasing hormone analog (LHRH-A)
Number of subjects: 21

Group type: COMPARATOR
Intervention: GH alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: GH + LHRH-A
Number of subjects: 21
Study: 9351556

Group type: EXPERIMENTAL
Intervention: Regular screening for prostate carcinoma
Number of subjects: 180000

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 180000
Study: 8475226

Group type: EXPERIMENTAL
Intervention: Delta sleep-inducing peptide (DSIP) 25 micrograms/kg bw IV over 30 min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Arginine chlorhydrate 0.5 g/kg bw IV over 30 min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Simultaneous DSIP plus arginine chlorhydrate administration
Number of subjects: 8

Group type: COMPARATOR
Intervention: DSIP 25 micrograms/kg bw from 2130h to 2230h
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo IV infusion
Number of subjects: 8